TD Waterhouse Canada Inc. Lowers Stake in Bristol Myers Squibb Company $BMY

TD Waterhouse Canada Inc. cut its stake in Bristol Myers Squibb Company (NYSE:BMY) by 93.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,089 shares of the biopharmaceutical company’s stock after selling 214,772 shares during the period. TD Waterhouse Canada Inc.’s holdings in Bristol Myers Squibb were worth $716,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Trifecta Capital Advisors LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $25,000. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb during the 2nd quarter valued at $25,000. Harbor Capital Advisors Inc. grew its position in shares of Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 313 shares in the last quarter. REAP Financial Group LLC increased its stake in shares of Bristol Myers Squibb by 202.8% during the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 428 shares during the period. Finally, Total Investment Management Inc. bought a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $38,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on BMY. The Goldman Sachs Group reissued a “neutral” rating and set a $57.00 target price (up previously from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Cantor Fitzgerald reissued a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, November 24th. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Piper Sandler reiterated an “overweight” rating and issued a $66.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a report on Wednesday, January 28th. Finally, HSBC reissued a “hold” rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Seven investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $57.43.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $55.85 on Tuesday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The business’s fifty day simple moving average is $53.58 and its 200-day simple moving average is $48.72. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. The company has a market cap of $113.70 billion, a PE ratio of 18.87, a PEG ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.5%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 85.14%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.